Zachary Klaassen discusses hydrogel spacer placement and resident education, drawing on approximately 250 Barrigel® procedures performed since FDA clearance in 2022. He describes ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...
Finally, current quality-of-life tools do not fully capture the patient experience. Emerging approaches incorporating patient ...
The 2026 SNMMI annual meeting featured a genitourinary diagnosis and imaging session, including a presentation by Dr. Surekha Yadav discussing longitudinal outcomes of PSMA PET/CT-detected bone ...
(UroToday.com) The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Akshay Bedmutha discussing the safety and efficacy of rechallenge PSMA ...
(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. David Cade presented LUTEON, an ongoing phase III trial ...
The 2026 SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kiflom Gebreslassea discussing a longitudinal analysis of estimated glomerular filtration rate ...
Dr. Peter O'Donnell presented patient-reported outcomes (PROs) from the phase III KEYNOTE-905/EV-303 trial evaluating perioperative enfortumab vedotin (EV) plus pembrolizumab in cisplatin-ineligible ...
A randomized, double-blind, active-control, multicenter phase 3 trial of casdatifan and cabozantinib versus placebo and cabozantinib in patients with advanced clear cell RCC. Treatment options remain ...
The 2026 ASCO annual meeting featured an oral abstract kidney cancer session and a presentation by Dr. Toni Choueiri discussing a ctDNA analysis in participants with renal cell carcinoma (RCC) treated ...
Predictors of treatment duration in patients with mHSPC treated with ENZA: A post hoc analysis of ARCHES. Prior analyses from the phase 3 ARCHES trial demonstrated significant improvements in ...
Genomic and transcriptomic correlates of deep PSA response in patients with mHSPC. Despite major advances in combination treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results